| Ivabradine | heart failure, in all type of patients | vs placebo | Cardiovascular death or hospital admission for CHF by 10% suggested heart failure death by 26% suggested hospitalisation for cardiovascular causes by 15% suggested CV death, MI hospitalization for HF by 10% suggested hospitalisation for heart failure by 17% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| death or hospitalization | no data | | Cardiovascular death or hospital admission for CHF | 0.90 [0.84 0.97] | p=0.04 | 0 | 17422 | 2 | SHIFT, BEAUTIFUL, | | heart failure death | 0.74 [0.58 0.94] | p=0.04 | 0 | 6505 | 1 | SHIFT, | | hospitalisation for cardiovascular causes | 0.85 [0.78 0.92] | p=0.04 | 0 | 6505 | 1 | SHIFT, | | CV death, MI hospitalization for HF | 0.90 [0.84 0.96] | p=0.04 | 0 | 17422 | 2 | SHIFT, BEAUTIFUL, | | Cardiovascular death | 0.99 [0.90 1.10] | p=1.00 | 0 | 17422 | 2 | SHIFT, BEAUTIFUL, | | hospitalisation for heart failure | 0.83 [0.76 0.91] | p=0.04 | 0 | 17422 | 2 | SHIFT, BEAUTIFUL, | | All cause death | 0.97 [0.89 1.05] | p=1.00 | 0 | 17422 | 2 | SHIFT, BEAUTIFUL, |
| Trial | Studied treatment | Control | Patients |
|---|
| SHIFT, 2010 | ivabradine | placebo | patients with NYHA class 2-4 heart failure, an LVEF <35%, a resting heart rate >70 bpm, and a heart-failure hospitalization within the previous year | | BEAUTIFUL, 2008 | ivabradine target dose of 7·5 mg twice a day
| placebo
| patients with coronary artery disease and left-ventricular systolic
dysfunction (LVEF <=40%)
|
| |
| Ivabradine | stable angina, in patients with left ventricular dysfunction | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| BEAUTIFUL, 2008 | ivabradine target dose of 7·5 mg twice a day
| placebo
| patients with coronary artery disease and left-ventricular systolic
dysfunction (LVEF <=40%)
|
| |
| Ivabradine | stable angina, in all type of patients | vs placebo on top of atenolol | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| ASSOCIATE (Tardif), 2009 | ivabradine 5 mg b.i.d. for 2 months, increased to 7.5 mg b.i.d. for a further 2 months (on top atenolol 50 mg/day )
| placebo on top atenolol 50 mg/day
| patients with stable angina receiving atenolol 50 mg/day or another beta-blocker at equivalent doses for at least
3 months
|
| |
| Ivabradine | | vs placebo on top of amlodipine | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| CL3-018 15mg, 3000 | ivabradine 7.5mg twice daily (15mg/d) | placebo | | | CL3-018 10mg, 3000 | ivabradine 5mg twice daily (10mg/d) | placebo | |
| |
| Ivabradine | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Borer (CL2-009) 5mg, 2003 | | | | | Borer (CL2-009) 10mg, 2003 | Ivabradine 5 mg twice daily (10mg/d)
| placebo
|
| | Borer (CL2-009) 20mg, 2003 | ivabradine 10mg twice daily (20mg/d)
| placebo
|
| | SIGNIFY, 2014 | ivabradine, at a dose of up to 10 mg twice daily, with the dose adjusted to achieve a target heart rate of 55 to 60 beats per minute. | placebo | patients who had both stable coronary artery disease without clinical heart failure and a heart rate of 70 beats per minute or more |
| |
| Ivabradine | | vs placebo (on top standard treatment) | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| BEAUTIFUL (angina subgroup), | ivabradine target dose of 7·5 mg twice a day
| placebo
| patients with stable
coronary artery disease and left ventricular
systolic dysfunction with limiting angina
|
| |
| Ivabradine | | vs atenolol | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| INITIATIVE (CL3-017, Tardif) 20mg, 2005 | ivabradine 5 mg bid for 4 weeks and then 10 mg bid for 12 weeks
| atenolol 50 mg od for 4 weeks and then 100 mg od for 12 weeks
| patients with stable angina
| | INITIATIVE (CL3-017, Tardif) 15mg, 2005 | ivabradine 5 mg bid for 4 weeks and then either 7.5 or 10 mg bid for 12 weeks
| atenolol 50 mg od for 4 weeks and then 100 mg od for 12 weeks
| patients with stable angina
|
| |
| Ivabradine | | vs amlodipine | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Ruzyllo (CL3-023) 15mg, 2007 | ivabradine 7.5mg twice daily | amlodipine 10mg once daily | Patients with a >/=3-month history of chronic, stable effort-induced angina | | CL3-023 (15mg), 0 | ivabradine 7.5mg twice daily
| amlodipine
|
| | CL3-023 (20mg), 0 | ivabradine 10mg twice daily
| amlodipine
|
| | Ruzyllo (CL3-023) 20mg, 2007 | ivabradine 10mg twice daily | amlodipine 10mg once daily | Patients with a >/=3-month history of chronic, stable effort-induced angina |
| |
